GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Starry Pharmaceutical Co Ltd (SHSE:603520) » Definitions » Beneish M-Score

Zhejiang Starry Pharmaceutical Co (SHSE:603520) Beneish M-Score : -2.89 (As of May. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Zhejiang Starry Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.89 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zhejiang Starry Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SHSE:603520' s Beneish M-Score Range Over the Past 10 Years
Min: -6.13   Med: -2.26   Max: 5.17
Current: -2.89

During the past 13 years, the highest Beneish M-Score of Zhejiang Starry Pharmaceutical Co was 5.17. The lowest was -6.13. And the median was -2.26.


Zhejiang Starry Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Zhejiang Starry Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Starry Pharmaceutical Co Beneish M-Score Chart

Zhejiang Starry Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.08 -2.26 -2.05 -2.38 -2.81

Zhejiang Starry Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.62 -2.67 -2.69 -2.81 -2.89

Competitive Comparison of Zhejiang Starry Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Starry Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Starry Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Starry Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Starry Pharmaceutical Co's Beneish M-Score falls into.



Zhejiang Starry Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zhejiang Starry Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7196+0.528 * 0.8688+0.404 * 1.0118+0.892 * 1.0424+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1135+4.679 * -0.024624-0.327 * 0.9859
=-2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥537 Mil.
Revenue was 642.301 + 565.084 + 547.023 + 517.971 = ¥2,272 Mil.
Gross Profit was 142.756 + 136.744 + 141.192 + 139.283 = ¥560 Mil.
Total Current Assets was ¥2,071 Mil.
Total Assets was ¥5,352 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,347 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥162 Mil.
Total Current Liabilities was ¥2,695 Mil.
Long-Term Debt & Capital Lease Obligation was ¥783 Mil.
Net Income was 12.283 + 4.915 + 4.042 + 25.708 = ¥47 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 92.09 + -6.965 + 95.409 + -1.809 = ¥179 Mil.
Total Receivables was ¥715 Mil.
Revenue was 565.908 + 754.164 + 434.608 + 425.169 = ¥2,180 Mil.
Gross Profit was 116.107 + 155.633 + 80.943 + 114.024 = ¥467 Mil.
Total Current Assets was ¥2,352 Mil.
Total Assets was ¥5,523 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,219 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥139 Mil.
Total Current Liabilities was ¥2,870 Mil.
Long-Term Debt & Capital Lease Obligation was ¥772 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(536.64 / 2272.379) / (715.378 / 2179.849)
=0.236158 / 0.328178
=0.7196

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(466.707 / 2179.849) / (559.975 / 2272.379)
=0.214101 / 0.246427
=0.8688

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2070.885 + 2347.476) / 5351.669) / (1 - (2352.091 + 2219.119) / 5523.251)
=0.174396 / 0.17237
=1.0118

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2272.379 / 2179.849
=1.0424

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2219.119)) / (0 / (0 + 2347.476))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(161.573 / 2272.379) / (139.2 / 2179.849)
=0.071103 / 0.063858
=1.1135

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((783.319 + 2695.14) / 5351.669) / ((771.642 + 2869.825) / 5523.251)
=0.649976 / 0.659298
=0.9859

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(46.948 - 0 - 178.725) / 5351.669
=-0.024624

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zhejiang Starry Pharmaceutical Co has a M-score of -2.89 suggests that the company is unlikely to be a manipulator.


Zhejiang Starry Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zhejiang Starry Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Starry Pharmaceutical Co (SHSE:603520) Business Description

Traded in Other Exchanges
N/A
Address
No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
Executives
Hu Jin Sheng Director

Zhejiang Starry Pharmaceutical Co (SHSE:603520) Headlines

No Headlines